drugset / Trial / NCT02973776

Vasoconstriction Trial With LEO 90100 Aerosol Foam

NCT02973776

Phase 1 Completed 36 enrolled LEO Pharma
RandomizedSingle-groupSingle-blindTreatment

Summary

Vasoconstriction study with LEO 90100

Timeline

Start
2016-12
Primary completion
2017-02
Completion
2017-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Betamethasone Other / unclassified 0.05 % Topical
Subject Calcipotriol Small molecule 0.005 % Topical
Subject Hydrocortisone Butyrate Unknown 0.1 % Topical
Subject Mometasone furoate Other / unclassified 0.1 % Topical
Subject clobetasol propionate Small molecule 0.05 % Topical

Indications